Sirona Biochem Announces Diabetes Preclinical Results in Chronic Study

Studies show the company's SGLT inhibitor normalizes diabetes and lowers fructosamine levels in test subjects.

Sirona Biochem Corp. announced today its lead compound for the treatment of Type 2 diabetes significantly reduced fructosamine levels in a chronic preclinical study.

In a 28-day chronic dosing study of obese diabetic rats, Sirona Biochem's SGLT (sodium glucose transporter) inhibitor, SBM-TFC-039, normalized diabetes and significantly lowered fructosamine levels. Fructosamine is a standard biomarker that reflects the level of glucose in the blood and that is commonly used for monitoring diabetes.

In the chronic study, SBM-TFC-039 also reduced blood glucose levels by 48% compared to the non-treated group. At the end of the study the ratio fructosamine total protein of the treated rats was reduced by 25% compared to the non-treated rats and was within 10% of the ratio for the control lean rats.

"We are very encouraged by the results we have obtained from our acute and chronic preclinical studies in the obese diabetic rat model," said Dr. Howard Verrico, President & CEO of Sirona Biochem. "Key members of our team, including our Scientific Advisory Board, will be meeting in Vancouver this week to refine our preclinical development plan," Dr. Verrico added.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.

Source: Sirona Biochem

 

No votes yet